Spots Global Cancer Trial Database for blinatumomab
Every month we try and update this database with for blinatumomab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | NCT06075238 | Leukemia, Lymph... | blinatumomab | 16 Years - 65 Years | Sichuan University | |
| Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT00560794 | Acute Lymphobla... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | NCT02101853 | Recurrent B Acu... | Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia | NCT02807883 | Acute Lymphobla... | Blinatumomab Hematopoietic C... | 1 Year - 70 Years | M.D. Anderson Cancer Center | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab | NCT06125106 | Acute Lymphobla... | Blinatumomab | 18 Years - 70 Years | Zhejiang University | |
| Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | NCT05559450 | B-cell Acute Ly... | Blinatumomab Conventional th... | 14 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT | NCT06061094 | Philadelphia Ch... | Imatinib Ponatinib Blinatumomab Indication for ... | 18 Years - 65 Years | Goethe University | |
| ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | NCT04785547 | ALL, Childhood Minimal Residua... | Blinatumomab | 6 Months - 21 Years | St. Anna Kinderkrebsforschung | |
| Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia | NCT03367299 | Acute Lymphoid ... Philadelphia Ch... | Chemotherapy + ... | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts | NCT03160079 | B-Cell Acute Ly... | blinatumomab pembrolizumab | 18 Years - | University of California, San Diego | |
| Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | NCT01209286 | B-ALL | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | NCT05559450 | B-cell Acute Ly... | Blinatumomab Conventional th... | 14 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL | NCT04448834 | B-cell Acute Ly... | Blinatumomab | 18 Years - | Duke University | |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia | NCT03628053 | Acute Lymphobla... | Tisagenlecleuce... Blinatumomab Inotuzumab | 18 Years - | Novartis | |
| Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT01471782 | Acute Lymphobla... | Blinatumomab | - 17 Years | Amgen Research (Munich) GmbH | |
| Immune Reconstitution After Allo-HSCT and Blinatumomab | NCT06075212 | Leukemia, Lymph... | blinatumomab | 16 Years - 65 Years | Sichuan University | |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) | NCT03298412 | High-risk Diffu... | Blinatumomab | 18 Years - 100 Years | Amgen | |
| Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma | NCT03173430 | Multiple Myelom... | Blinatumomab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot | NCT04723342 | Childhood Acute... | Blinatumomab | 1 Year - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT01466179 | Acute Lymphobla... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL | NCT03751709 | B-Cell Acute Ly... ALL, Adult B-ALL | Blinatumomab Haplo-Mismatche... | 18 Years - | Cedars-Sinai Medical Center | |
| Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | NCT00274742 | Non-Hodgkin's L... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | NCT04872790 | B Acute Lymphob... B Acute Lymphob... Mixed Phenotype... Recurrent B Acu... Recurrent Mixed... | Dasatinib Methotrexate Prednisone Rituximab Venetoclax Blinatumomab Bone Marrow Asp... Lumbar Puncture Biospecimen Col... | 18 Years - | OHSU Knight Cancer Institute | |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | NCT02003222 | Acute Lymphobla... B Acute Lymphob... | Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging | 30 Years - 70 Years | National Cancer Institute (NCI) | |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | NCT03117751 | Acute Lymphobla... Acute Lymphobla... | Prednisone Vincristine Daunorubicin Pegaspargase Erwinase® Cyclophosphamid... Cytarabine Mercaptopurine Dasatinib Methotrexate Blinatumomab Ruxolitinib Bortezomib Dexamethasone Doxorubicin Etoposide Clofarabine Vorinostat Idarubicin Nelarabine Thioguanine Asparaginase Er... Calaspargase Pe... | 1 Year - 18 Years | St. Jude Children's Research Hospital | |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | NCT02997761 | Adult B Acute L... Philadelphia Ch... | Blinatumomab Ibrutinib | 18 Years - | University of California, Davis | |
| Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | NCT01741792 | Diffuse Large B... | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | NCT03914625 | B Acute Lymphob... B Lymphoblastic... Down Syndrome | Asparaginase Er... Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Leucovorin Calc... Mercaptopurine Mercaptopurine ... Methotrexate Pegaspargase Prednisolone Prednisone Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul... | 365 Days - 31 Years | National Cancer Institute (NCI) | |
| Study in Adult Ph-positive ALL | NCT04688983 | Acute Lymphobla... | Ponatinib Blinatumomab Imatinib | 55 Years - | Cardiff University | |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia | NCT02877303 | B Acute Lymphob... B Lymphoblastic... | Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Inotuzumab Ozog... Laboratory Biom... Mercaptopurine Methotrexate Ofatumumab Prednisone Rituximab Vincristine Sul... | 14 Years - | M.D. Anderson Cancer Center | |
| A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL) | NCT06124157 | B Acute Lymphob... | Biospecimen Col... Blinatumomab Bone Marrow Bio... Calaspargase Pe... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Doxorubicin Echocardiograph... Leucovorin Mercaptopurine Methotrexate Multigated Acqu... Pegaspargase Prednisolone Prednisone Radiation Thera... Thioguanine Vincristine | 366 Days - 46 Years | National Cancer Institute (NCI) | |
| Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | NCT02412306 | Relapsed Refrac... | Blinatumomab | 0 Years - | Amgen | |
| A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma | NCT02961881 | Non-Hodgkin's L... | blinatumomab | 18 Years - | Amgen | |
| Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | NCT02003222 | Acute Lymphobla... B Acute Lymphob... | Allogeneic Hema... Biospecimen Col... Blinatumomab Bone Marrow Asp... Bone Marrow Bio... Cyclophosphamid... Cytarabine Daunorubicin Daunorubicin Hy... Dexamethasone Etoposide Lumbar Puncture Mercaptopurine Methotrexate Pegaspargase Prednisone Rituximab Vincristine Vincristine Sul... X-Ray Imaging | 30 Years - 70 Years | National Cancer Institute (NCI) | |
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | NCT03263572 | Accelerated Pha... Acute Lymphobla... BCR-ABL1 Fusion... Blast Phase Chr... Philadelphia Ch... Recurrent Acute... Refractory Acut... t(9;22) | Blinatumomab Cytarabine Methotrexate Ponatinib | 18 Years - | M.D. Anderson Cancer Center | |
| Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | NCT03072771 | Diffuse Large B... | Blinatumomab Autologous stem... Carmustine Etoposide Cytarabine Melphalan Peripheral bloo... | 18 Years - | Washington University School of Medicine | |
| Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | NCT04334993 | Philadelphia-Ne... High-Risk Cance... | Blinatumomab | 18 Years - 30 Years | Israeli Medical Association | |
| Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | NCT05559450 | B-cell Acute Ly... | Blinatumomab Conventional th... | 14 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2019 Pilot | NCT04723342 | Childhood Acute... | Blinatumomab | 1 Year - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | NCT03914625 | B Acute Lymphob... B Lymphoblastic... Down Syndrome | Asparaginase Er... Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Leucovorin Calc... Mercaptopurine Mercaptopurine ... Methotrexate Pegaspargase Prednisolone Prednisone Radiation Thera... Radiation Thera... Thioguanine Vincristine Sul... | 365 Days - 31 Years | National Cancer Institute (NCI) | |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | NCT05327894 | Acute Lymphobla... Mixed Phenotype... | Blinatumomab Blinatumomab | 1 Day - 365 Days | Princess Maxima Center for Pediatric Oncology | |
| Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL | NCT06111625 | Leukemia, Lymph... | blinatumomab | 16 Years - 65 Years | Sichuan University | |
| Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | NCT05182385 | ALL, Recurrent,... | Blinatumomab Venetoclax | 18 Years - | Goethe University | |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma | NCT02568553 | Recurrent Burki... Recurrent Diffu... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Gray-... Recurrent Mantl... Recurrent Margi... Recurrent Media... Recurrent Non-H... Recurrent Small... Refractory Burk... Refractory Diff... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Gray... Refractory Mant... Refractory Marg... Refractory Medi... Refractory Non-... Refractory Smal... | Blinatumomab Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT03318770 | Acute Lymphobla... | Dasatinib and b... | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT06308588 | Philadelphia Ch... Acute Lymphobla... | Blinatumomab Asciminib | 18 Years - | M.D. Anderson Cancer Center | |
| Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant | NCT04044560 | B-cell Adult Ac... Stem Cell Leuke... Minimal Residua... | blinatumomab | 1 Year - | University of British Columbia | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | NCT03982992 | B Cell Precurso... B-Cell Acute Ly... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Blinatumomab in... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT04329325 | Acute Lymphobla... Philadelphia Ch... | Blinatumomab dasatinib dexamethasone methotrexate | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma | NCT03173430 | Multiple Myelom... | Blinatumomab | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML | NCT03595917 | B-cell Acute Ly... Chronic Myeloid... Philadelphia Ch... | ABL001 Dasatinib Prednisone Blinatumomab | 18 Years - | Dana-Farber Cancer Institute | |
| Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT03476239 | Acute Lymphobla... | Blinatumomab Dexamthasone | 18 Years - | Amgen | |
| Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT03476239 | Acute Lymphobla... | Blinatumomab Dexamthasone | 18 Years - | Amgen | |
| Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL | NCT00274742 | Non-Hodgkin's L... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | NCT04530565 | B Acute Lymphob... | Biospecimen Col... Blinatumomab Bone Marrow Asp... Cyclophosphamid... Cytarabine Dasatinib Dexamethasone Doxorubicin Hyd... Echocardiograph... Electrocardiogr... Lumbar Puncture Mesna Methotrexate Multigated Acqu... Ponatinib Hydro... Prednisone Vincristine Sul... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | NCT03605589 | Leukemia, B-cel... Lymphoma, B-Cel... | Blinatumomab Pembrolizumab | 1 Year - 40 Years | Children's Hospital Medical Center, Cincinnati | |
| Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) | NCT04554485 | Lymphoblastic L... Ph Negative ALL Newly Diagnosed | Blinatumomab | 18 Years - 65 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation | NCT05837689 | Acute Lymphobla... | Blinatumomab | 1 Year - 18 Years | The Children's Hospital of Zhejiang University School of Medicine | |
| Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation | NCT06339775 | Acute B-cell Ly... | Blinatumomab | - 65 Years | The First Affiliated Hospital of Zhengzhou University | |
| Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab | NCT06125106 | Acute Lymphobla... | Blinatumomab | 18 Years - 70 Years | Zhejiang University | |
| Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL | NCT04524455 | Acute Lymphobla... | Blinatumomab AMG 404 Dexamethasone P... | 18 Years - 99 Years | Amgen | |
| Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | NCT05519579 | Acute Lymphobla... | Methotrexate Blinatumomab | 18 Years - | Northside Hospital, Inc. | |
| Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | NCT03643276 | Acute Lymphobla... | Blinatumomab Bortezomib Cyclophosphamid... Cytarabine Daunorubicin Myocet Dexamethasone Doxorubicin Etoposide Fludarabine Pho... Ifosfamide 6-Mercaptopurin... Methotrexate Pegaspargase Prednisolone Tioguanin Vincristine Vindesine Erwinase | - 17 Years | University Hospital Schleswig-Holstein | |
| Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL | NCT05557110 | B Acute Lymphob... | Blinatumomab | 15 Years - 65 Years | The First Affiliated Hospital of Soochow University | |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | NCT03512405 | CD19 Positive Philadelphia Ch... Recurrent Acute... Refractory Acut... | Blinatumomab Laboratory Biom... Pembrolizumab | 18 Years - | City of Hope Medical Center | |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | NCT02101853 | Recurrent B Acu... | Allogeneic Hema... Asparaginase Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Leucovorin Calc... Mercaptopurine Methotrexate Mitoxantrone Mitoxantrone Hy... Pegaspargase Pharmacological... Radiation Thera... Therapeutic Hyd... Thioguanine Vincristine Vincristine Sul... | 1 Year - 31 Years | National Cancer Institute (NCI) | |
| Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | NCT04329325 | Acute Lymphobla... Philadelphia Ch... | Blinatumomab dasatinib dexamethasone methotrexate | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | NCT01209286 | B-ALL | Blinatumomab | 18 Years - | Amgen Research (Munich) GmbH | |
| Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma | NCT03605589 | Leukemia, B-cel... Lymphoma, B-Cel... | Blinatumomab Pembrolizumab | 1 Year - 40 Years | Children's Hospital Medical Center, Cincinnati | |
| Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia | NCT04994717 | Newly Diagnosed... | Blinatumomab Low-intensity c... SOC chemotherap... | 40 Years - 100 Years | Amgen | |
| Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | NCT02997761 | Adult B Acute L... Philadelphia Ch... | Blinatumomab Ibrutinib | 18 Years - | University of California, Davis | |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | NCT04546399 | Down Syndrome Recurrent B Acu... | 3-Dimensional C... Blinatumomab Cyclophosphamid... Cytarabine Dexamethasone Etoposide Hydrocortisone ... Leucovorin Calc... Mercaptopurine Methotrexate Nivolumab Pegaspargase Thioguanine Vincristine Sul... | 1 Year - 30 Years | National Cancer Institute (NCI) | |
| D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | NCT02744768 | Acute Lymphobla... | Dasatinib Blinatumomab | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma | NCT02961881 | Non-Hodgkin's L... | blinatumomab | 18 Years - | Amgen | |
| D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia | NCT02744768 | Acute Lymphobla... | Dasatinib Blinatumomab | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia | NCT03109093 | ALL, Recurrent,... | Blinatumomab | 18 Years - | Goethe University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
